Author details

Full Name

Margaret Rees

Affiliation

ORCID

Career Start Year

1982

Papers

212

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37658015	Editors, publication ethics and maintaining the integrity of the scientific record.		2024
36472224	Subjective aging: factors influencing individuals' perspectives.	International Psychogeriatrics	2023
37845136	EMAS position statement: Testosterone replacement therapy in older men.		2023
37701397	Research ethics, consent and publication.		2023
37954227	Artificial intelligence, authorship and publication of case reports.		2023
36769563	Vitamin D, Menopausal Health and COVID-19: Critical Appraisal of Current Data.		2023
36566517	EMAS position statement: Vitamin D and menopausal health.		2023
35059307	Case reports: Advancing knowledge of rare or unusual medical conditions.	Case Reports in Women's Health	2022
35569270	Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society.		2022
35115178	The essential menopause curriculum for healthcare professionals: A European Menopause and Andropause Society (EMAS) position statement.	Maturitas	2022
34686433	Menopausal hormone therapy in women with benign gynaecological conditions and cancer.		2021
33896654	Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide.		2021
34274202	Global consensus recommendations on menopause in the workplace: A European Menopause and Andropause Society (EMAS) position statement.	Maturitas	2021
33127864	Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer.	Int J Gynecol Cancer	2021
33008675	Management of urinary incontinence in postmenopausal women: An EMAS clinical guide.		2021
32682573	The Mediterranean diet and menopausal health: An EMAS position statement.		2020
32368505	Writing case reports, consent for publication and General Data Protection Regulation (GDPR).	Case Reports in Women's Health	2020
31740049	Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement.		2020
32059825	European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis.	Maturitas	2020
32046979	European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis.	Int J Gynecol Cancer	2020
32209279	Menopause symptom management in women with dyslipidemias: An EMAS clinical guide.		2020
32861483	Menopausal Hormone Therapy and breast cancer risk: Individualization is the key to safety.		2020
30670234	Complementary and integrative therapies for menopause.	Complementary Therapies in Medicine	2019
31027683	EMAS position statement: Predictors of premature and early natural menopause.		2019
30732930	Menopause: Women should not suffer in silence.		2019
30952373	On the use and abuse of register studies: The case of menopausal hormone therapy.		2019
29065996	Joint Opinion Paper- "Ageing and sexual health'' by the European Board & College of Obstetrics and Gynaecology (EBCOG) and the European Menopause and Andropause Society (EMAS).	European Journal of Obstetrics, Gynecology and Reproductive Biology	2018
28919172	Comments on the USPSTF draft recommendation statement on menopausal hormone therapy: Primary prevention of chronic conditions.		2018
30314563	Menopause and diabetes: EMAS clinical guide.		2018
29444759	Current management of pelvic organ prolapse in aging women: EMAS clinical guide.		2018
29169584	Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide.		2018
29594004	Publication of medical case reports and the CARE guidelines.	Case Reports in Women's Health	2018
27802892	Osteoporosis management in patients with breast cancer: EMAS position statement.		2017
28389043	Interventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Postition Statement.		2017
28539165	Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement.		2017
28483346	Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.		2017
28927651	Health and wellbeing after cancer.		2017
29593998	Publication of medical case reports and consent.	Case Reports in Women's Health	2017
27621230	A model of care for healthy menopause and ageing: EMAS position statement.		2016
27389038	Revised global consensus statement on menopausal hormone therapy.	Maturitas	2016
27333031	Donor-specific antibodies require preactivated immune system to harm renal transplant.	eBioMedicine	2016
27180162	Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS).		2016
27322027	Revised Global Consensus Statement on Menopausal Hormone Therapy.	Climacteric	2016
26857884	EMAS recommendations for conditions in the workplace for menopausal women.		2016
26614257	EMAS position statement: Testosterone replacement therapy in the aging maleâ¿.		2016
27660085	Aging and anti-aging.		2016
25982505	EMAS position statement: Non-hormonal management of menopausal vasomotor symptoms.		2015
25757366	EMAS position statement: The ten point guide to the integral management of menopausal health.		2015
25924648	Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.		2015
25771039	Menopausal hormone therapy and ovarian cancer: Putting risk into perspective.		2015